Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

University Medical Center Groningen, Groningen

Octapharma Research Site, Washington D.C.

Hôpital Purpan - Centre de Traitment Regional de l'Hemophilie Pole, Toulouse

Octapharma Research Site, Miami

Octapharma Research Site, Memphis

Centre Régional de Traitement de l'hémophilie, Nantes

Octapharma Research Site, Indianapolis

Octapharma Research Site, Chicago

Centre Régional de Traitement de l'Hémophilie, Bron

Octapharma Research Site, Houston

Octapharma Research Site, Aurora

Octapharma Research Site, Salt Lake City

Octapharma Research Site, Sacramento

Centre Hospitalier Universitaire Félix Guyon, La Réunion

Octapharma Research Site, Edmonton

Octapharma Research Site, St. John's

University Hospital Centre Zagreb, Zagreb

CHU Estaing, Clermont-Ferrand

Nagoya University Hospital, Nagoya

Hospital of the Univ of Occupational and Environmental Health, Kitakyushu

St. Marianna Univ School of Medicine Hospital, Kawasaki

Nara Medical University Hospital, Kashihara

Gunma University Hospital, Maebashi

Osaka National Hospital, Osaka

Ogikubo Hospital, Tokyo

Teikyo University Hospital, Tokyo

PHI Institute of Transfusion Medicine of Republic of Macedonia, Skopje

University Medical Centre Ljubljana, Ljubljana

McMaster University, Hamilton

Helsinki University Hospital, Helsinki